Oxford BioMedica PLC provided revenue guidance for the rest of 2013 and 2014. During the rest of 2013 and 2014, the company reported that revenues are expected to be generated from intellectual property, development and manufacturing alliances and a potential significant option fee that may arise should Sanofi choose to exercise its option over RetinoStat(Registered).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
317 GBX | -0.94% | -5.23% | +44.32% |
May. 09 | Avon Protection wins UK MoD supply deal; Molten Ventures up | AN |
May. 09 | Molten Ventures wins UK MoD supply contract | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.32% | 403M | |
+5.53% | 111B | |
+11.87% | 106B | |
-12.53% | 22.24B | |
+0.17% | 21.25B | |
-4.92% | 18.97B | |
-35.21% | 18.52B | |
-11.13% | 16.81B | |
+37.76% | 12.54B | |
-25.05% | 8.09B |
- Stock Market
- Equities
- OXB Stock
- News Oxford Biomedica plc
- Oxford BioMedica PLC Provides Revenue Guidance for the Rest of 2013 and 2014